A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

This study is testing a new experimental drug, ASP5834, designed to block specific proteins that help cancer cells grow. By targeting these mutations, researchers hope to find a safer and more effective way to treat solid tumors that have not responded to standard therapies.

This trial is for adults with solid tumors—such as colorectal, lung, or pancreatic cancer—that have spread or cannot be removed by surgery. To join, your cancer must have specific KRAS gene mutations, and you must have already tried standard treatments that were either unsuccessful or not suitable for you.

You will receive the treatment through a vein (infusion) during cycles that last 3 or 4 weeks. Throughout the study, you will have regular clinic visits for health checks, blood tests, and scans to monitor how your cancer is responding and to ensure the treatment is safe for you.

The study is currently recruiting participants in several U.S. locations, including Santa Monica, CA; Atlanta, GA; and Jefferson, LA. The expected time in the study is about one year, though this may vary based on your individual health needs.